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Abstract
Background: The detection of insulin autoantibodies (IAA) aids in the prediction of autoimmune diabetes
development. However, the long-standing, gold standard
125I-insulin radiobinding assay (RBA) has low
reproducibility between laboratories, long sample processing times and requires the use of newly synthesized
radiolabeled insulin for each set of assays. Therefore, a rapid, non-radioactive, and reproducible assay is highly
desirable.
Methods: We have developed electrochemiluminescence (ECL)-based assays that fulfill these criteria in the
measurement of IAA and anti-insulin antibodies (IA) in non-obese diabetic (NOD) mice and in type 1 diabetic
individuals, respectively. Using the murine IAA ECL assay, we examined the correlation between IAA,
histopathological insulitis, and blood glucose in a cohort of female NOD mice from 4 up to 36 weeks of age. We
developed a human IA ECL assay that we compared to conventional RBA and validated using samples from 34
diabetic and 59 non-diabetic individuals in three independent laboratories.
Results: Our ECL assays were rapid and sensitive with a broad dynamic range and low background. In the NOD
mouse model, IAA levels measured by ECL were positively correlated with insulitis severity, and the values
measured at 8-10 weeks of age were predictive of diabetes onset. Using human serum and plasma samples, our IA
ECL assay yielded reproducible and accurate results with an average sensitivity of 84% at 95% specificity with no
statistically significant difference between laboratories.
Conclusions: These novel, non-radioactive ECL-based assays should facilitate reliable and fast detection of
antibodies to insulin and its precursors sera and plasma in a standardized manner between laboratories in both
research and clinical settings. Our next step is to evaluate the human IA assay in the detection of IAA in
prediabetic subjects or those at risk of type 1 diabetes and to develop similar assays for other autoantibodies that
together are predictive for the diagnosis of this common disorder, in order to improve prediction and facilitate
future therapeutic trials.
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Autoimmunity occurs when the physiologic mechanisms
of immune tolerance fail to curtail aberrant activation
and effector activity of self-reactive lymphocytes [1,2].
Type 1 diabetes (T1D) is an autoimmune disease
wherein insulin deficiency results from the destruction
of insulin-secreting b cells in the pancreas by infiltrating
T cells and other cells of the immune system [3]. As a
consequence, individuals with diabetes depend on
administration of exogenous insulin and are susceptible
in the longer term to complications including retinopa-
thy, nephropathy, and cardiovascular disease [3]. The
diagnosis and etiology of T1D appears to be widely vari-
able [4], with poorly defined environmental factors act-
ing upon underlying genetic susceptibility to cause
disease in humans [5]. Clinical manifestations of T1D
occur once a substantial proportion of the insulin-pro-
ducing b cells are destroyed [6]. The development of
autoantibodies against multiple islet cell antigens is a
well-established feature of T1D [7,8]. Although not an
active component of the disease process itself, the pre-
sence of circulating autoantibodies to two or more islet
antigens, namely insulin (IAA), glutamic acid decarboxy-
lase (GADA), islet antigen 2 (IA-2A), and zinc transpor-
ter-8 (ZnT8A), is highly predictive when combined with
a family history of the disease or genetic risk [7-13].
IAA are usually the first islet autoantibodies to appear
in prediabetic children [14-16], making it one of the ear-
liest measurable signs of the autoimmune process.
Furthermore, evidence suggests that mean IAA levels,
but not of IA-2A or GADA, can serve as a predictive
marker of diagnosis [17-19].
In the non-obese diabetic (NOD) mouse, one of the
most extensively studied animal models of T1D, it has
been reported that IAA levels correlate with both age
of disease onset [15,20] and insulitis across mice in a
strain-dependent manner [21]. NOD mice sponta-
neously develop autoimmune diabetes that shares
numerous characteristics with the human form of the
disease. In both humans and NOD mice, multiple
genetic loci contribute to diabetes susceptibility with
the MHC locus being the most prominent susceptibil-
ity locus [22]. Typically, leukocytic infiltration of the
islets begins around 4 weeks of age in the NOD
mouse. This slowly progresses to more severe insulitis
with beta cell destruction and ultimately results in
frank diabetes including glucose intolerance between
12-16 weeks of age [23]. Approximately 60-80% of the
females and 20-30% of the males eventually develop
diabetes by 30 weeks of age [24]. No evidence has yet
been reported that the levels of IAA in an individual
mouse predict its specific risk for T1D onset and
insulitis.
The radiobinding assay (RBA) is currently the most
widely used method for assessing autoantibody levels
including IAA, as enzyme-linked immunosorbent assays
(ELISAs) have not equaled or surpassed the conven-
tional RBA in performance for detecting IAA [25-27].
Although the RBA is the gold standard for measuring
IAA, the RBA approach possesses several drawbacks
including: i) a requirement for newly synthesized radi-
olabeled insulin for each set of assays; ii) the need to
g e n e r a t ean e ws t a n d a r dc u r v eu s i n gac o n f i r m e dI A A
sample; iii) a lengthy procedure spanning numerous
steps over multiple days; iv) an inability to distinguish
between different IAA immunoglobulin subtypes; v)
non-specific interference by soluble factors including
anti-bovine serum albumin (BSA) antibodies; and, most
importantly, vi) inconsistent results across laboratories
worldwide [26,28-30]. A more rapid, non-radioactive,
and more reproducible assay for measuring IAA to facil-
itate T1D prediction is urgently needed.
To progress toward a better analytic tool for autoanti-
body detection in individuals genetically at-risk for T1D
development, we investigated electrochemiluminescence
(ECL)-based assays for measuring IAA in mice and IA
in humans. Unlike mouse IAA, human IA detected in
samples from insulin-treated diabetic individuals are
likely to consist of both IAA produced during the auto-
immune response against endogenous insulin as well as
antibodies arising as a consequence of repeated exogen-
ous insulin administration. IA are detectable by both
RBA and ELISA, but it has been reported that IA
detected by ELISAs using plate-bound insulin are less
relevant to the autoimmune process [25,31]. Neverthe-
less, plasma or serum samples from established T1D
individuals are readily available and, therefore, we have
examined IA in insulin-treated diabetic individuals as
the first step toward developing an ECL assay for IAA
detection in prediabetic samples. ECL has been used in
clinical laboratory tests because it is fast, easy to per-
form, non-radioactive, and highly sensitive with a broad
dynamic range [32]. ECL is currently used to detect a
wide range of analytes [33,34] including biomarkers for
Alzheimer’s disease [35], meningitis [36], and HIV infec-
tion [37]. Several studies have also shown that ECL can
outperform conventional ELISAs in both speed and sen-
sitivity [38,39].
In the NOD mouse model, we demonstrate that our
IAA ECL method is highly sensitive and that IAA levels
show a strong correlation with insulitis and are predic-
tive of diabetes on a mouse-to-mouse basis. This simple
murine IAA ECL assay can be completed in as little as
2-3 hours, requires only a few microliters of serum, and
has a broad dynamic range with little background. The
mouse assay format, however, could not be directly
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developed a new assay using the same ECL platform to
detect human IA. This human IA ECL method could
accurately and reproducibly distinguish samples from
diabetic and non-diabetic individuals. These data indi-
cate that the ECL approach described here has promise
for further development into a clinical test for T1D risk
using samples from prediabetic and newly-diagnosed
diabetic individuals who have not been treated with exo-
genous insulin.
Methods
Mice
NOD/ShiLtJ mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). All mice were maintained
at the NIAID animal facility and cared for in accordance
with institutional guidelines. All mice experiments were
performed at NIAID in compliance with the guidelines
of the NIAID/NIH Institutional Animal Care and Use
Committee (IACUC). Breeders were injected with a sin-
g l ed o s eo f5 0μL of complete Freund’sA d j u v a n t( C F A ,
Sigma-Aldrich, St. Louis, MO) in the hind footpad to
p r e v e n tt h e mf r o md e v e l o p i n gd i a b e t e s[ 4 0 ] .F o rt h e
insulitis study, only female NOD mice from the third or
later litters of each breeder female were used due to
lower diabetes incidence in the first two litters after
CFA injection.
Human samples
Human plasma samples of known RBA IA status (five
IA-positive long-standing diabetic individuals; 4 IA-
negative long-standing diabetic individuals and 20 IA-
negative non-diabetic individuals) were purchased from
Bioreclamation, LLC, Hicksville, NY. Ten IA-positive
plasma samples from long-standing diabetic individuals
were obtained from the UK GRID diabetic cases collec-
tion (http://www.childhood-diabetes.org.uk/grid.shtml)
and plasma and serum samples from the same ten long-
standing diabetic individuals from the Genes and Pheno-
types of Type 1 Diabetes collection (http://www.t1-dia-
betes.org.uk) at the University of Cambridge. These
samples were collected with ethical approval from the
National Health Service Cambridgeshire Research Ethics
Committee and written consent was obtained from all
individuals or parents of individuals who were too
young to consent. Plasma samples from 59 healthy non-
diabetic individuals of unknown IAA status were pur-
chased from George King Biomedical Inc., Overland
Park, KS. Thirty-four serum samples were obtained
from long-standing diabetic subjects who consented to
and enrolled in the NIH protocol, The Natural History
of Autoimmune Diabetes and Its Complications
(NCT00896610) approved by the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK)
institutional review board.
Participating laboratories for human ECL assay evaluation
Initial human IA ECL assay development was conducted
at Wellstat Diagnostics in Gaithersburg, MD, USA
(Lab1-Wellstat). To examine the reproducibility of the
assay, the same samples from the 34 diabetic and 59
healthy non-diabetic individuals were further evaluated
at test sites at the Laboratory of Immunology, National
Institute of Allergy and Infectious Disease in Bethesda,
MD, USA (Lab2-NIAID); and the JDRF/Wellcome Trust
Diabetes and Inflammation Laboratory, University of
Cambridge in Cambridge, UK (Lab3-DIL).
Assessment of diabetes in NOD mice
Mice were monitored for T1D onset by measurement of
blood glucose levels weekly using an Accu-Chek Advan-
tage
® meter (Roche, Mannheim, Germany). Non-fasting
blood glucose levels ≥ 200 mg/dL for two consecutive
weeks indicated T1D onset.
Murine IAA ECL assay
Streptavidin Dynabeads
® M-280 were obtained from
Invitrogen (Oslo, Norway). Recombinant human insulin
(MBL
® International Corporation, Woburn, MA) was
biotinylated using Biotin-LC-Sulfo-NHS Ester (Pierce
Biotechnology, Rockford, IL), conjugated to the strepta-
vidin Dynabeads, and stored at 4°C until used. For the
IAA ECL assay (Figure 1A), the insulin-conjugated
beads were pre-blocked with skim milk (BD Difco™,
Sparks, MD) in phosphate-buffered saline (PBS) with
0.3% Tween 20 (Sigma-Aldrich) for 60 minutes and
then incubated with 50 μL per well of a 1:100 dilution
of mouse serum or mouse monoclonal antibody to insu-
lin (ABCAM, Cambridge, MA) in triplicate for 60 min-
utes while shaking in a 96-well plate. The beads were
washed and retained in the wells by a magnet. Next, the
beads were resuspended in ECL Assay Buffer (PBS with
0.5% BSA + 0.3% Tween 20) plus an anti-mouse IgG
secondary antibody (BioVeris™, Gaithersburg, MD) con-
jugated to Tris(bipyridine)ruthenium(II) cation [Ru(bipy)
3]
2+ and diluted in StabilCoat (Surmodics, Eden Prairie,
MN). The plate was then incubated with shaking for 30
minutes at room temperature in an M-SERIES
® M1MR
analyzer (BioVeris™) followed by electrochemilumines-
cence measurement. M1MR analyzer solutions include:
GLO Solution, CLEAN Solution, STORE Solution, and
DILUENT Solution (provided by Wellstat Diagnostics,
LLC, Gaithersburg, MD). Human serum samples tested
using this assay format used a ruthenylated anti-human
IgG secondary antibody (Wellstat Diagnostics, LLC,
Gaithersburg, MD).
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Pancreata were removed from female mice at various
ages from 5-20 weeks and fixed in 10% formalin. Paraf-
fin-embedded tissue sections were prepared and stained
with hematoxylin and eosin (H&E) by Histoserv, Inc.
(Germantown, MD). Insulitis was scored as previously
described [41]. At least four sections from each pancreas
were examined and on average ≥ 40 islets per pancreas
were scored. Only seven of the 58 mice had fewer than
40 islets scored; four mice had > 25 islets scored, and
three mice had few identifiable islets with severe insulitis
(15-19 islets).
Study of IAA correlation with insulitis in NOD mice
Blood glucose levels in female NOD mice were mea-
s u r e da n ds e r u mw a sc o l l e c t e do n c eaw e e kf r o m4
weeks up to 20 weeks of age. Serum was stored at -80°C
until tested. IAA and insulitis in the prediabetic phase
were examined, while diabetic mice were excluded.
Fifty-eight mice were sacrificed at various ages and their
pancreata were removed for histological examination
and insulitis scoring as described above. IAA levels were
measured in triplicate using the ECL assay and normal-
ized to the signal measured with beads alone (no serum
added).
Longitudinal IAA versus diabetes onset study in NOD
mice
Fifty-four NOD females were monitored for develop-
ment of T1D from 4 weeks up to 36 weeks of age.
Blood glucose levels were assessed and serum was col-
lected every 1.5-2 weeks. Serum was stored frozen at
-80°C until tested. Serum IAA values were measured in
triplicate for each mouse at each time point by ECL as
described above. IAA value is calculated as signal over
background signal from negative control sera. ECL sig-
nals from the negative control sera were negligible; i.e.,
IAA value was approximately 1.0-1.2. The negative con-
trol sera were from non-diabetic NOD mice from the
first litter of the CFA-treated breeders. Receiver operat-
ing characteristic (ROC) curves were generated using
the IAA values at 7, 8/8.5, or 10 weeks of age for the
NOD mice that did or did not develop diabetes by 20
weeks of age. Threshold values for a “positive” predictive
(of later diabetes development) IAA measurement were
based on IAA values with the highest likelihood ratios
calculated from the ROC curve analyses. Since our
NOD mouse colony has a diabetes incidence of about
40% by 20 weeks, we also chose the 60
th percentile as
an alternative threshold for a “positive” predictive IAA
measurement. Using these thresholds, we calculated the
sensitivity, specificity, positive predictive value, and
negative predictive value for diabetes prediction at 7,
8.5, and 10 weeks of age.
Human IA ECL diluents
Two diluents manufactured by Wellstat Diagnostics
(Gaithersburg, MD) were utilized throughout the assay:
Human Sample Diluent (HSD) and Human Assay Dilu-
ent (HAD). HSD consists of deoinized water (Millipore,
6WHS%ORFNLQVXOLQERXQG
 PDJQHWLFEHDGV
 PLQKU
6WHS,QFXEDWHVHUXP
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6WHS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 VHFRQGDU\
6WHS3ODFHLQ005DQDO\]HUWRLQFXEDWH
	VKDNHPLQWKHQUHDG
a6KDNLQJa
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Figure 1 Protocol for murine IAA ECL assay. A) Overview of the murine IAA ECL procedure. B) IAA in serum is precipitated by biotinylated-
insulin conjugated to streptavidin-coated magnetic beads, while a ruthenium (Ru)-tagged secondary antibody detects the bound IgG
autoantibodies. 2° = secondary.
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Page 4 of 16Billercara, MA), sodium phosphate-monobasic (Sigma-
Aldrich), sodium phosphate-dibasic (Sigma-Aldrich),
sodium chloride (Sigma-Aldrich), bovine serum albumin
(SeraCare, Milford, MA), bovine IgG (Millipore), 2-
Methyl-4-isothiazoline-3-one hydrochloride (MIT)
(Sigma-Aldrich), 30% Brij-35 solution (Sigma-Aldrich),
MAK-3 IgG Poly (Roche, Chicago, IL), HBR-1 (Roche)
and pH adjusted to 7.2 ± 0.10. The solution is sterile fil-
tered and stored at 2-8°C. The formulation for HAD is
the same, with the addition of polyvinylpyrrolidone
(Sigma-Aldrich) and polyvinyl alcohol (Sigma-Aldrich)
prior to the pH adjustment. Additional diluents used in
the operation of the BioVeris M1MR analyzer include:
DILUENT Solution, STORE Solution, GLO Solution,
and CLEAN Solution.
ECL-based assay for the detection of human IA
The assay is based on the same technology as the murine
IAA ECL test. Briefly, 30-35 μL of serum or plasma were
diluted 1:10 in HSD in 1.5 mL polypropylene straight-
walled tubes (VWR). M-270 Streptavidin (SA) Dynabeads
(Invitrogen), pre-washed with HSD, were then added to a
final concentration of 0.4 mg/mL, incubated at 25°C for 15
minutes with gentle mixing in a pre-clearing step, spun
briefly at 1000 × g, and magnetized for 3 minutes to
remove the beads. The bead-free supernatant was har-
vested into a fresh tube and remagnetized for 2 minutes
before 50 μL of sample was transferred to each of six wells
of a 96-well polypropylene plate. 25 μL/well of either
HAD or 50 ng/mL biotin-insulin in HAD was then added
to triplicate wells. The plate was sealed and incubated for
120 minutes with constant shaking (1400 RPM at 25°C,
throughout protocol). Then 25 μL/well of HAD washed
M-270 SA Dynabeads (0.4 mg/mL) were added to all assay
wells, followed by a 30 minute incubation with shaking. A
plate magnet (LifeSep) was applied for 2 minutes to isolate
IA/insulin complexes, which were then washed with HSD
twice by shaking the plate for 2 minutes, with plate mag-
net separations for 2 minutes between each step. One
hundred μLo f0 . 3 0μg/mL Wellstat TAG-goat anti-
human Fc was then added to each well and incubated for
60 minutes with shaking. The plate was then washed with
Assay Run Diluent (ARD) as described above and then the
beads were resuspended in 150 μL ARD, and evaluated
using the M1MR Analyzer. Specificity was determined by
competition in which varying concentrations of non-bioti-
nylated insulin were added to the samples followed by
shaking at 1400 rpm at 25°C for 60 minutes prior to incu-
bation with biotinylated insulin.
Statistics
ROC curves were generated and analyzed using Prism
software (GraphPad, San Diego, CA). Spearman’s corre-
lation coefficients (rs) and corresponding p-values were
calculated using S-Plus (TIBCO Software Inc., Palo Alto,
CA) or R (http://www.r-project.org/) statistical software.
Pearson’s coefficients were determined using Prism Soft-
ware (Graphpad) and compared according to the
method described by Hanley, J.A. et al. [42]. Linear
regression was used to analyze variability in the deter-
mined IAA values and sample ranks within cohorts
using Prism software.
Results
An ECL assay developed for the detection of IAA in NOD
mice is sensitive and specific with a broad dynamic range
To develop a murine IAA assay that does not require
the use of radioactivity or lengthy incubation times, we
took advantage of ECL technology in which a lumines-
cent signal is generated by a reaction involving a ruthe-
nium (Ru) conjugate at the surface of an electrode [43].
The assay is performed in a 96-well format using two
microliters of serum per mouse in 2.5 hours (Figure
1A). Magnetic beads coated with insulin were used to
capture IAA from serum, and a polyclonal secondary
anti-IgG antibody labeled with the ruthenium chelate,
Tris(bipyridine)ruthenium(II) cation [Ru(bipy)3]
2+
(TAG) was used to detect bead-bound IAA remaining
after washing the wells with magnetic retention of the
beads (Figure 1A and 1B). The redox reaction between
Ru and the substrate tripropylamine (TPA) that occurs
near the electrode is a regenerative process that allows
for an ECL signal that amplifies over time (Figure 2A).
Background signal is very low as photons can be gener-
ated only in the electric field near the electrode surface
when the Ru is brought into proximity with the elec-
trode by the magnet. To examine the dynamic range
and specificity of the assay, we used a mouse monoclo-
nal antibody against insulin and determined that our
ECL assay can discriminate antibody concentrations
from less than 10 pg/mL to greater than 100 ng/mL
(Figure 2B). No appreciable signal was measured with
an isotype control primary antibody. We next evaluated
the ability of the assay to detect IAA in murine serum.
Little to no ECL signal was detected in samples from
non-diabetic mouse strains, including the C57BL/6 and
BALB/c strains, in contrast to the robust signal in the
majority of 8 week-old NOD mice (Figure 2C). These
data demonstrate that our IAA ECL assay is specific and
can potentially detect serum insulin autoantibody levels
over a nearly 5-log concentration range.
Insulin autoantibody measured by ECL in NOD mice
peaks at approximately 8-10 weeks of age
We next sought to evaluate the variations in IAA levels
in individual mice during the progression to disease in
the NOD mouse model for T1D. Female NOD mice
were individually followed from 4 weeks of age to up to
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every 1.5 weeks to determine IAA and blood glucose
levels. We found that IAA levels peaked or achieved a
plateau at approximately 8-10 weeks of age in mice that
became diabetic by 20 weeks of age (Figure 3A and 3B).
The majority of these mice did not develop diabetes
until 16 weeks of age or later (Figure 3C), but after
reaching 10 weeks of age the serum IAA levels began to
drop markedly, but never returned to baseline levels
before the mice had to be sacrificed due to disease. The
average IAA levels in mice that were not diabetic by 20
weeks of age were lower and peaked later (Figure 3A,
95% confidence interval).
Insulin autoantibody levels measured by ECL correlate
with insulitis severity in NOD mice
We next determined the physiologic utility of the ECL
measurements by comparing IAA levels with insulitis
severity in histological sections of the pancreas in indivi-
dual NOD mice at various ages. Insulitis severity was
determined for each mouse using an insulitis index as
outlined in Figure 4A. We consistently observed a
higher insulitis index in animals with elevated IAA
levels. Moreover, insulitis severity was correlated with
the maximum IAA value better than with the final IAA
measurement taken at the time the pancreas was
removed for histology (rs = 0.793 vs 0.736, respectively,
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Page 6 of 16Figure 4C and 4B, top panels). The correlation coeffi-
cients were stronger with the 5-10 week old mice (Fig-
ure 4B and 4C, middle panels) compared to the data set
containing older mice (Figure 4B and 4C, top panels).
The age-dependence of the correlation of IAA values
with insulitis is further demonstrated by the loss of cor-
relation with increasing age of the analyzed mice (Figure
4B and 4C, bottom panels). These results demonstrate
that ECL measured IAA levels provide a reliable indica-
tor of autoimmune destruction of the pancreatic islets
accessible in the blood.
Insulin autoantibody levels measured by ECL can be used
to predict T1D in NOD mice
As IAA levels measured by the ECL method correlated
with insulitis in NOD mice, we hypothesized that we
could use IAA measurements to predict diabetes diag-
n o s i s .W e ,t h e r e f o r e ,f o llowed 54 mice over 20 weeks,
monitoring blood glucose levels and collecting serum
samples every 1.5 weeks. Using receiver-operating char-
acteristic (ROC) analysis, we determined that IAA values
measured between 8 and 10 weeks of age were most
predictive of diabetes (Figu r e5 ) .T h eR O Cp l o t si l l u s -
trate that the greatest ratio of ‘%s e n s i t i v i t y ’ to ‘100 - %
specificity’ (maximum likelihood ratio) was obtained
when measuring IAA between 8 and 10 weeks of age
rather than 7 or 12 weeks of age (Figure 5 and data not
shown). Next, we calculated the sensitivity, specificity,
positive predictive values, and negative predictive values
based on IAA thresholds determined by ROC analysis
(Table 1). In our colony the diabetes cumulative fre-
quency for female NOD mice is about 40% by 20 weeks;
therefore, a secondary analysis was performed wherein
the thresholds corresponded to the 60
th percentile for
this cohort of NOD mice (Table 2). IAA values over the
threshold calculated from both analyses at 8.5 and 10
weeks were highly predictive of diabetes onset by 20
weeks of age (Tables 1 and 2, and Figure 6). The sensi-
tivity and specificity using the threshold from the ROC
analysis to predict diabetes were 80% and 93%, respec-
tively at 8.5 weeks, and 84% and 93%, respectively at 10
weeks. The positive and negative predictive values were
91% and 84%, respectively at 8.5 weeks, and 91% and
86%, respectively at 10 weeks. Thus, the ECL values
measured at 8.5 weeks were highly predictive of eventual
diagnosis of diabetes by 20 weeks of age in NOD mice.
Measurement of IA in human samples using the ECL
platform
As the murine IAA ECL assay was capable of measuring
IAA levels that were predictive of diabetes diagnosis in
NOD mice and also effectively monitored the develop-
ment of the underlying insulitis, we used this assay to
evaluate human samples of known IA status as
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Figure 3 IAA levels peak at age 8-10 weeks for NOD that
become diabetic by 20 weeks. IAA levels were followed in NOD
mice from 4 weeks up to 36 weeks. A) IAA values from mice that
developed diabetes by 20 weeks are plotted, with each line
depicting the data from a single mouse. The IAA levels from mice
that had an IAA value below the positive predictive threshold at 8.5
weeks (described in Table 1) are represented by dotted lines. The
95% confidence interval of IAA values from mice not diabetic by 20
weeks (shaded region, n = 22-29) is plotted for comparison. B) IAA
values were normalized to the highest IAA value for each mouse (n
= 18-25). The average (avg) IAA values at the indicated ages are
graphed. Data after the age of 18 weeks are calculated from an avg
of less than 10 mice due to euthanasia of diabetic mice. C) Percent
of diabetes-free mice from 4 weeks up to 20 weeks are plotted (n =
54). The number of mice that became diabetic at each time point is
indicated by bars. IAA value is calculated as the average signal from
triplicate wells divided by the background signal from triplicate
wells with negative control sera.
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Page 7 of 16determined by RBA. The assay was, however, unable to
distinguish between the IA
+ and IA
- donors with many
samples producing high ECL signal independent of anti-
body status (Figure 7). This result was not entirely unex-
pected as others have reported non-specific interfering
factors when assessing IAA in human samples [29]. As
ECL-based assays have previously been successfully used
in human plasma and serum samples for other analytes,
we were confident that the ECL platform could still
allow for the sensitive detection of human antibodies
against insulin. Therefore, we developed a new assay to
reduce the background signal and examined its ability to
A) discriminate between samples of unknown IA status
and B) distinguish non-diabetic from long-standing dia-
betic individuals. Figure 8 displays the design of the
method utilized to measure IA in human serum or
plasma. Absorbed plasma or serum samples are incu-
bated with or without (HSD only) biotinylated-insulin,
which is captured by streptavidin (SA)-coupled magnetic
beads, and bound antibody is detected by a secondary
antibody tagged with the Ruthenium reagent (TAG).
Signal is evaluated using the M1MR Analyzer which
employs a magnet to capture the bead-IA-Ig:Tag com-
plex into an electric field for the ECL reaction [14]. The
IA value obtained for each sample is calculated by divid-
ing the average signal obtained from wells incubated
Figure 4 Insulitis index correlates with murine IAA ECL values. NOD mice were followed from 4 weeks up to 20 weeks of age. Serum
samples were collected weekly and IAA levels were measured by our murine IAA ECL assay. Mice were euthanized at various ages and
pancreatic tissue was extracted and stained with H&E. A) Insulitis was scored as depicted in the H&E stained tissue sections. The formula for
calculating insulitis index is indicated below. B) Insulitis index was correlated with the IAA values at the age the pancreas was removed for
histology (final measurement). C) Insulitis index was correlated with the maximum IAA values measured for each mouse during the study. Data
were plotted for NOD pancreas tissues obtained from mice at 5-20 weeks and 5-10 weeks of age. IAA value is calculated as the average signal
from triplicate wells divided by the background signal from triplicate wells with beads alone. The Spearman’s correlation coefficient (rs) and the
corresponding p-value for each age group are displayed on the graphs. The trends showing highest correlation (rs values) when restricting the
analysis to younger mice is graphed (bottom panels), where the x-axis is the upper age limit (in weeks) of the mice included in the analysis.
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Page 8 of 16with biotinylated-insulin by the average of the signal
from three wells without biotinylated-insulin. Prelimin-
ary data suggested that the background could be
reduced and signal enhanced in human plasma or
serum samples (Figure 9A).
The human IA ECL assay is specific, reproducible, and
correlates well with RBA in samples from diabetic
individuals
To confirm the specificity of the ECL signal, we per-
formed a competition assay using non-biotinylated
insulin with several samples of known IA status deter-
mined by RBA. Increasing amounts of non-biotinylated
insulin incrementally reduced the IA value (Figure 9A
and 9B). We next carried out ROC analysis with 25 IA
negative samples and 15 IA positive samples as pre-
v i o u s l yd e t e r m i n e db yR B A .W ef o u n dt h a tw i t h i nt h i s
small cohort, we could accurately distinguish between
the two groups with 94% sensitivity at 100% specificity
and an area-under-the curve (AUC) value of 0.94 [95%
confidence interval (95% CI): 0.98 to 1.01] (Figure 9C).
Finally, we examined the lot-to-lot reproducibility of our
reagents and determined that IA levels from the same
samples were stable across two independently prepared
batches of biotinylated insulin, and TAG-secondary anti-
body (Figure 9D).
The human IA ECL assay can distinguish disease status
from donor plasma and serum
Having established that our IA ECL assay is stable,
reproducible across batches of reagents, and consistent
with IA status determined by RBA, we examined
whether it could distinguish between long-standing dia-
betic and non-diabetic individuals. Plasma samples from
59 non-diabetic donors (30 males, 29 females; mean age:
28.6 years) and serum samples from 34 long-standing
diabetic donors (11 males, 21 females; mean age: 38.2
years) were evaluated using our assay with three differ-
ent instruments in three separate laboratories. IA values
in plasma or serum samples obtained from the same
individual did not differ significantly (data not shown).
The ROC analysis of the IA values revealed no statisti-
cally significant difference between the three laboratories
(P > 0.5) in determining donor disease status (Figure
10A). Our assay distinguished IA levels in diabetic
donors across a 3-log range while the distribution across
non-diabetic donors remained tightly clustered around
an IA value of 1.5 (95% CI: 1.3-1.6), enabling a
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Figure 5 ROC analysis of sensitivity-to-specificity ratios for IAA
values in 7-10 week old mice. Area under the curve (AUC) is
shown for each age analyzed. Receiver operating characteristic
(ROC) curves were generated using the IAA values at the indicated
ages for the NOD mice that did or did not develop diabetes by 20
weeks of age.
Table 1 IAA levels over a threshold calculated by ROC analyses predict T1D by 20 weeks
7 wk 8.5 wk 10 wk
Diabetic by 20 wk Diabetic by 20 wk Diabetic by 20 wk
(+) (-) Total (+) (-) Total (+) (-) Total
IAA > Threshold (+) 11 2 13 20 2 22 21 2 23
IAA < Threshold (-) 14 27 41 5 27 32 4 25 29
Total 25 29 54 25 29 54 25 27 52
Sensitivity 0.44 0.80 0.84
Specificity 0.93 0.93 0.93
Positive Predictive Value 0.85 0.91 0.91
Negative Predictive Value 0.66 0.84 0.86
The thresholds for a positive (+) predictive IAA measurement were chosen based on IAA values with the maximum likelihood ratio calculated from the ROC
analyses for the NOD mice at 7, 8-8.5, and 10 weeks of age. The number of mice that do (+) or do not (-) develop diabetes by 20 weeks of age and had IAA
values greater (+) or less (-) than the threshold are displayed in each column. The IAA threshold for mice at 7, 8.5, and 10 weeks are 176, 115, and 190,
respectively. Mice not tested at the specified age were considered to have a positive predictive IAA level if the IAA values were greater than the threshold on the
week prior and following the specified age.
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Page 9 of 16sensitivity of 88% at 95% specificity (Figure 10B). Com-
parison of the intra-cohort rank for each sample by the
individual laboratories versus the mean rank across the
three laboratories revealed a strong correlation of indivi-
dual rank versus mean rank (r
2 = 0.92, 0.87, 0.87 respec-
tively for Lab1-Wellstat, Lab2-NIAID, Lab3-DIL) with
no significant differences between laboratories (P =
0.83) (Figure 10C).
Discussion
The primacy of the immune response to insulin and its
precursors in the etiology of T1D is evident from the
fact that IAA is often the earliest autoantibody to appear
in children destined to be diagnosed with T1D [16,44];
in contrast to other autoantibodies that appear before
diagnosis of T1D, mean IAA levels predict age-at-diag-
nosis [17-19]; and a polymorphism just 5’ of the struc-
tural gene, insulin, regulates its transcription in thymus
and alters risk of T1D [45]. In the NOD mouse model
the autoimmune response to insulin is essential for
development of the disease [46]. Therefore, optimizing
the testing of IAA is highly desirable. In the present
study, we describe novel methods of measuring IAA in
prediabetic mice and IA in diabetic human samples that
overcome some of the limitations of RBAs. The use of
non-radioactive insulin and stable TAG-secondary anti-
body enabled us to utilize the same materials in three
separate laboratories without reagent deterioration over
t h ec o u r s eo fm u l t i p l ea s s a y s .T h i si sas i g n i f i c a n t
improvement over the conventional RBA method of
detection, which requires radioactive
125I-insulin that
must be freshly synthesized before each series of assays
[30]. Clarification of human samples with SA-beads to
remove non-specifically bound materials significantly
decreased background while maintaining specific signal.
This clearance step overcomes challenges present in the
RBA where assay components including BSA [29]
reduce the specificity of that IA assay format. The ECL
assay requires the same sample volume per well used in
RBA but does not require the generation of a standard
curve using known positive samples (Table 3) [30].
Furthermore, the combined incubation time achieves a
> 30-fold reduction in assay time compared to the RBA
[30] and the stable IA values we obtain from multiple
batches of reagents demonstrate that the assay is suita-
ble for longitudinal studies where reproducible, reliable,
comparable measurements are critical.
In our investigation of NOD mice, we have shown
that the murine IAA ECL assay is extremely sensitive,
highly correlative with the degree of insulitis, and is pre-
dictive of later development of diabetes in individual
mice. The dynamic range can span up to five log units
(Figure 2B &10B), which is about three logs greater than
the capability of most chromogenic ELISAs. This is
enabled by the Ru ECL species that is recycled rather
than consumed during the generation of the ECL signal,
allowing each ruthenium tag to emit multiple photons
which further amplifies the signal [43]. Our ECL techni-
que uses biotinylated-insulin to bind to streptavidin-
coated magnetic beads. The use of the streptavidin-bio-
tin system for linkage of antigens in immunosorbent
assays has been shown to be superior in preserving anti-
gen conformation and antibody-binding capacity to the
adsorption methods of immobilizing antigens used in
most ELISAs [47]. The assay also uses very small
amounts of serum and is much faster than available
R B A sa n dE L I S A s[ 2 7 ]w i t hr e s u l t so b t a i n e di n2 . 5
hours.
The value of this ECL assay in measuring IAA as a
marker of b cell damage is demonstrated by our finding
that IAA ECL values from NOD mice directly correlate
w i t ht h ed e g r e eo fi n s u l i t i s( F i g u r e4 ) .T h eo b s e r v e d
decline in IAA levels late in the disease progression
(Figure 3) may be due to the decrease in available auto-
antigen as the beta cells are destroyed [13]. Thus, the
correlation between IAA and insulitis would be expected
Table 2 IAA levels greater than the 60
th percentile predict T1D by 20 weeks
7 wk 8.5 wk 10 wk
Diabetic by 20 wk Diabetic by 20 wk Diabetic by 20 wk
(+) (-) Total (+) (-) Total (+) (-) Total
IAA > Threshold (+) 17 5 22 20 3 23 18 2 20
IAA < Threshold (-) 8 24 32 5 26 31 7 25 32
Total 25 29 54 25 29 54 25 27 52
Sensitivity 0.68 0.80 0.72
Specificity 0.83 0.90 0.93
Positive Predictive Value 0.77 0.87 0.90
Negative Predictive Value 0.75 0.84 0.78
The thresholds for a positive (+) predictive IAA measurement were chosen as the 60
th percentile in the NOD mice of the specified age. Displayed in each column
are numbers of mice that do (+) or do not (-) develop diabetes by 20 weeks of age and had IAA values greater (+) or less (-) than the threshold. IAA thresholds
for 7, 8.5, and 10 week old mice are 47, 100, and 252, respectively. Mice not tested at the specified age were considered to have a positive predictive IAA level if
the IAA values were greater than the threshold on the week prior and following the specified age.
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Page 10 of 16to be more profound when IAA levels are on the rise,
which for NOD mice is before 10 weeks of age. In some
mice the IAA levels may have peaked prior to the final
time point collected; therefore, the maximum IAA level
measured over the time course examined for each
mouse may be a more accurate estimate of the
underlying insulitis severity. This is supported by the
stronger correlation between IAA and insulitis when
analyzing maximum IAA levels measured for each
mouse rather than the IAA levels at the final time point
when insulitis was assessed (Figure 4B and 4C). The
strong correlation of IAA and insulitis in NOD mice
supports the ability of our murine IAA ECL assay to
measure disease progression on a mouse-to-mouse basis.
Beyond evaluating the course of the disease, the mur-
ine IAA ECL assay was able to successfully predict
which 8-10 week old NOD mice would later go on to
develop diabetes by 20 weeks of age. The high predictive
value achievable by our method (approximately 90%,
Tables 1 and 2) effectively allows a researcher to con-
s i d e ra n8 - w e e k - o l dm o u s et ob ei n e v i t a b l yd i a b e t i c ,
eliminating the need to wait an additional 12 or more
weeks to determine whether disease will develop. Accu-
rate prediction of T1D onset at an early age in mice will
facilitate therapeutic experiments that seek to prevent
disease development. Our determined threshold IAA
values and the optimal age for diabetes-predictive IAA
measurement may be specific to our NOD colony since
diabetes incidence and age of onset differs between
N O Dc o l o n i e s[ 4 8 , 4 9 ] .H o w e v e r ,c o l o n y - d e p e n d e n t
values could be established and utilized across time due
to the stability of signal in our assay format. These fea-
tures could enable researchers to utilize a murine IAA
E C La s s a yt or e l i a b l ym o n i t o rt h ea u t o i m m u n ea t t a c k
on b cells.
Our ongoing work is aimed at developing an assay
sensitive and specific enough to diagnose insulitis based
o nap o s i t i v et e s t ,o rs e r i es of tests, for IAA and its
levels and to facilitate prediction of the progression to
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Figure 6 IAA levels measured at 8-10 weeks of age can
distinguish mice progressing to disease. Positive predictive IAA
thresholds for each age were calculated as in Table 1 and are
indicated by the dotted lines. IAA values measured at 7, 8-8.5, and
10 weeks of age are shown for each mouse that did (Db+) or did
not (Db-) become diabetic by 20 weeks. IAA value is calculated as
the average signal from triplicate wells divided by the background
signal from triplicate wells with negative control sera.
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Figure 7 Using the murine IAA ECL format, IA negative and IA
positive individuals cannot be distinguished. Serum from 23
individuals (IA
-, n = 14; IA
+, n = 9) measured for IA by RBA were
tested for IA using the murine IAA ECL format, but with an anti-
human IgG ruthenium-labeled secondary. IA value is calculated as
the average signal from triplicate wells divided by the background
signal from triplicate wells with beads alone. NS = non-significant.
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Figure 8 Schematic diagram of ECL-based assay for human IA. A) Non-specifically binding material is removed from 1:10 diluted serum or
plasma by incubation with streptavidin coated paramagnetic beads (SA-beads), followed by magnetic removal to yield a clarified sample. B)
Biotinylated-insulin is incubated with the clarified sample and binds to IA in solution. C) Bound IA-biotinylated insulin complexes are precipitated with
SA-beads. D) Ruthenium-labeled secondary goat anti-human IgG antibody binds to IA-bead complexes and is detected on the M1MR Analyzer.
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Figure 9 Evaluation of specificity and stability of the ECL-based assay for human IA. A) Samples from five IA+ and one IA- donors as
determined by RBA were incubated with an increasing percentage of non-biotinylated insulin prior to addition of biotinylated insulin. B)
Example dataset from the competition assay for one IA+ and one IA- donor. IA value for each donor was determined from the mean signal
from triplicate wells with insulin divided by the mean signal from triplicate background wells without insulin. C) Curve generated by ROC
analysis of the ability of the ECL assay to distinguish between samples of RBA determined IA status. Analysis was performed using Prism
software. D) Samples from IA+ and IA- donors were used to evaluate the reproducibility of the ECL assay across multiple batches of reagents.
TAG-IgG = ruthenium labeled goat anti-human IgG secondary antibody. HAD = Human Assay Diluent.
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Figure 10 Performance, dynamic range, and reproducibility of the ECL-based IA assay across three independent test sites.P l a s m a
samples from 59 non-diabetic individuals (30 males, 29 females, Mean Age: 28.61 ± 8 yr) and serum samples from 34 long-standing diabetic
individuals (11 males, 21 females, Mean Age: 38.23 ± 15.73) were evaluated using our human IA ECL-assay at three separate laboratories. A) IA
values from all samples were analyzed by receiver operating characteristic (ROC) analysis for the ability to distinguish between non-diabetic and
diabetic donors. B) Plot of mean values obtained across the three test sites for each sample. Samples could be distinguished by IA values
spanning a 3-log range (0.77-943.3). A cutoff IA value of 3.0 (dashed line) determined by ROC analysis of these samples. C) Plot of ascending
intra-laboratory rank vs ascending mean rank for the 93 samples across the three test sites. Samples were ranked 1 through 93 in order of
increasing IA value as determined by our IA ECL assay. Black circles = Lab 1 (Wellstat), black squares = Lab 2 (NIAID), and black triangles = Lab 3
(DIL). All statistical analyses were performed using Prism software. *AUC, Area under the curve;
† 95% CI, 95% confidence interval; AS95 =
sensitivity at 95% specificity; Lab1-Wellstat = Wellstat Diagnostics in Gaithersburg, MD, USA. Lab2-NIAID = Laboratory of Immunology, National
Institute of Allergy and Infectious Disease in Bethesda, MD, USA; and Lab3-DIL = Diabetes and Inflammation Laboratory, University of Cambridge
in Cambridge, UK.
Table 3 Comparison of operational characteristics of conventional RBA and our ECL-based assay for human IA
Radiobinding Assay* ECL
† Assay
Input Material Serum or Plasma Serum or Plasma
Input Volume 5 μL/well (10 μL total) 5 μL/well (30 μL total)
Isotypes Detected IgA, IgG, IgM IgG
Detection Agent Radioactive I
125-insulin Non-radioactive anti-human IgG-TAG
Time to Result 4 days 6 hours
Standard Curve Yes No
Maximum Reported AS95
|| 74% 88%
Maximum Reported AUC
¶ (95%CI
#) 0.91 (085-0.96) 0.97 (0.92-1.01)
*All information regarding radiobinding assay performance has been collected from the 2010 report by Schlosser et al. [26]. †ECL, Electrochemiluminescence; ||
AS95, Sensitivity at 95% specificity ¶AUC, area under the curve, calculated from the ROC curve used to assess the ability of each assay to distinguish between
non-diabetic and long-standing diabetic individuals; #CI95, 95% confidence interval
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robustly in any clinical laboratory. Future intervention
or prevention trials in T1D could target the early anti-
preproinsulin autoimmune response, not least because it
is probably the major etiological trigger of the disease in
children.
In our studies thus far, we have evaluated IA in
plasma and serum samples from long-standing insulin-
treated diabetic individuals rather than from prediabetic
or newly-diagnosed individuals that have not been trea-
ted with insulin. Several reports have identified quantita-
tive and qualitative differences in the IAA detectable in
insulin-untreated diabetic individuals compared to IA
present in samples from individuals receiving exogenous
insulin including varying affinities, epitope preference,
and usage of subtypes of IgG isotype IAA [50-54]. How-
ever, each of these studies utilized only a small number
(< 15) of samples, were conducted before the wide-
spread use of human recombinant insulin and rapid-act-
ing analogs, and did not examined the change in
affinity, isotype utilization, or epitope specificity of anti-
bodies before and after the onset of exogenous insulin
therapy in the same individuals. Therefore, it has not
been definitively demonstrated that the antibodies exam-
ined in insulin-treated diabetic individuals are exclu-
sively or predominantly generated de novo in response
to exogenous antigen administration. Moreover, it is
likely that the widespread detection of IA in insulin-
treated diabetic individuals is due, at least in part, to
anamnestic responses of memory B cells and plasma
cells generated during the insulitic phase of the autoim-
mune attack on pancreatic b cells. Consequently, IAA
levels would be predicted to decrease as insulin levels
decline over the course of disease progression as we and
others have observed in the NOD mouse model and
prediabetic human samples (Figure 3B) [15,19]. There-
fore, before our assay can be used to examine IAA in
prediabetic individuals and to dissect the complexity of
the immune response to the renewed presence of auto-
antigen in the form of exogenous insulin therapy, it will
be critical to enhance the sensitivity of our assay while
maintaining a very high specificity. We are presently
exploring ways to achieve the goal of increased sensitiv-
ity for human IAA detection and T1D prediction in pre-
diabetic samples. Our ongoing efforts include
exploitation of the regenerative photon emission enabled
by ECL technology and the incorporation a competition
assay for samples that are near the cutoff threshold to
ensure the detection of insulin-specific IgG. We also
plan to incorporate multiple autoantibody testing into
our ECL assay to improve identification of prediabetic
individuals in the general population, including IA-2A
and GADA [7,8,12,55,56].
Conclusions
Based on these results we are optimizing our human IA
assay for the detection of IAA in prediabetic individuals,
with the ultimate goal of facilitating intervention early
in the autoimmune process in prediabetic individuals to
limit or prevent b cell loss and delay T1D diagnosis.
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